Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes

被引：0
|
作者：
Junko Oya
Tomoko Nakagami
Yukiko Hasegawa
Yuichiro Kondo
Aki Katamine
Mika Shimizu
Ryo Kubota
Rika Suda
Tetsuya Babazono
机构：
[1] Tokyo Women’s Medical University School of Medicine,Division of Diabetology and Metabolism, Department of Internal Medicine
来源：
Diabetology International | 2024年 / 15卷
关键词：
Type 2 diabetes; Insulin degludec/liraglutide; Insulin degludec/insulin aspart; HbA1c;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：237 / 243
页数：6
相关论文
共 50 条
  • [1] Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes
    Oya, Junko
    Nakagami, Tomoko
    Hasegawa, Yukiko
    Kondo, Yuichiro
    Katamine, Aki
    Shimizu, Mika
    Kubota, Ryo
    Suda, Rika
    Babazono, Tetsuya
    [J]. DIABETOLOGY INTERNATIONAL, 2024, 15 (02) : 237 - 243
  • [2] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/ASPART VERSUS BIPHASIC INSULIN ASPART IN PATIENTS WITH TYPE 2 DIABETES IN IRAN
    Saiyarsarai, P.
    Khosroshahi, Ghazizadeh A.
    Khedmati, J.
    Ghaffari, S.
    Soleymani, F.
    Seyyedifar, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S576 - S576
  • [3] Evaluation of the CGMs in type-2 diabetic patients switched from Liraglutide and Insulin Degludec to Liraglutide and Insulin Degludec/Aspart
    Kakizaki, Yusuke
    Fujita, Tomoko
    Takahashi, Tomono
    Miwa, Takashi
    Odawara, Masato
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S111 - S111
  • [4] Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
    Luo, Qiong
    Zhou, Li
    Zhou, Naitong
    Hu, Ming
    [J]. FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [5] COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Liu, C.
    Tao, L. B.
    Wang, F.
    [J]. VALUE IN HEALTH, 2020, 23 : S111 - S111
  • [6] COST-EFFECTIVENESS ANALYSIS OF INSULIN DEGLUDEC/INSULIN ASPART VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Xu, J.
    Lan, K.
    Wang, J.
    [J]. VALUE IN HEALTH, 2020, 23 : S111 - S111
  • [7] Insulin degludec and insulin degludec/insulin aspart: A guide to their use in diabetes mellitus
    Keating G.M.
    [J]. Drugs & Therapy Perspectives, 2013, 29 (10) : 297 - 302
  • [8] Insulin Degludec and Insulin Degludec/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus
    Gillian M. Keating
    [J]. Drugs, 2013, 73 : 575 - 593
  • [9] Insulin Degludec and Insulin Degludec/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus
    Keating, Gillian M.
    [J]. DRUGS, 2013, 73 (06) : 575 - 593
  • [10] Insulin Degludec/Liraglutide: A Review in Type 2 Diabetes
    Sarah L. Greig
    Lesley J. Scott
    [J]. Drugs, 2015, 75 : 1523 - 1534
12345